To evaluate serum markers of bone resorption, formation, and mineralization during 1 year of secukinumab treatment in AS patients in daily clinical practice.
Latest Information Update: 24 Jun 2022
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
Most Recent Events
- 24 Jun 2022 New trial record
- 04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism